drugset / Trial / NCT00546780
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Comparator | tanespimycin | Unknown | 340 mg/m2 | Intravenous |